|Day Low/High||38.16 / 38.62|
|52 Wk Low/High||27.88 / 40.97|
BMY sees reason for optimism over the final half of the year.
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.
It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.
Plus, Russia could provide a real-time clinical trial of a coronavirus vaccine.
Let me disabuse you of some of the biggest canards that people routinely spout involving the Fed and stocks.
How I'd play the Golden Arches after its quarter pounding.
Negotiations on the next round of stimulus, more so than tension between Washington and Beijing, and more so than earnings season, will control short-term financial market performance.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Plus, why shares of vaccine maker Moderna are taking a hit.
If you are out of step with the marketplace, do not blame the marketplace. Understand that you have failed to adapt.
The hitch is that fundamentals do matter, too. Confused? Let's examine what's happening in the market and why it's making me cautious.
The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.
The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.
What if the market is simply pricing in a quarter that had already been priced out?
Equity markets had a tougher day on Wednesday than immediately meets the eye. And did you catch what Trump said?
I would wait until the next down day, and there will be one.
Do you know what a company does, does it do it well, and is there anything going on that could change the trajectory?
That's the really good news about why we could bounce back so quickly from Thursday's debacle.
The administration will provide increased financial support to 5 pharmas working on Covid vaccines, and we must keep an eye on price action in this uncertain market.
We're cheering what may be an aberration, a bullish employment number. We'll take what it brings - a wholesale shift in what we're buying and what we're selling to fund it.
Taking a chunk of Pfizer during this selloff, while Amazon has raised $10 billion in mixed-maturity debt and all eyes are on the government's response to civil unrest in the U.S.
WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
I've been long Merck for a long time, since way before this pandemic became part of our lives.
The return of NYSE floor traders is symbolic of the return to normalcy, as vaccine candidate manufacturers are scaling up for mass production.
As State economies begin the slow process of reopening, the Fed is there to support market function. Facebook's latest e-commerce foray has investors cheering.
Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.
I'm long this name, as I am several of the others involved. Will I add on a day like this?
Jerome Powell hit the airwaves with some words of caution and comfort. Nvidia is running into earnings.